Recently, Director Xiang Yang’s team at the Gynecological Oncology Center of PUMCH published a prospective study of CAP01 in The Lancet Oncology journal, which studied the treatment effect of an immune checkpoint inhibitor developed by Chinese pharmaceutical factory (brand-name drug Camrelizumab) in combination with Apatinib (an anti-angiogenic drug) in patients with high-risk chemo-resistant/recurrent gestational trophoblastic neoplasms (GTN). This study brings new hope to patients with high-risk chemo-resistant/recurrent GTN. This is globally the first prospective phase II clinical trial study that uses an immune checkpoint inhibitor in combination with an anti-angiogenic drug to treat high-risk chemo-resistant/recurrent GTN, involving the largest sample size for this rare disease reported by a single institution so far.

The CAP01 research published by Director Xiang Yang’s team

Journalist: Zhang Yaning

Photo courtesy of the Gynecological Oncology Center

Translator: Liu Haiyan

Editor: Yang Jie and Wang Yao